

1634
JRW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/902,176	
	Filing Date	July 10, 2001	
	First Named Inventor	Stefan Schreiber	
	Art Unit	1634	
	Examiner Name	Sally A. Sakelaris	
Total Number of Pages in This Submission	4+6cites	Attorney Docket Number	25481-P001X1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Supplemental Information Disclosure Statement; Form SB/08B, 6 cites; return post card
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Winstead Sechrest & Minick P.C.		
Signature	<i>Melissa D. Schwaller</i>		
Printed name	Melissa D. Schwaller		
Date	February 14, 2005	Reg. No.	46,089

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature	<i>Viola M.L. Ange</i>		
Typed or printed name	Viola M.L. Ange	Date	Feb. 14, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ATTORNEY DOCKET NO.
25481-P001X1

PATENT
APPLICATION NO. 09/902,176



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Stefan Schreiber et al.

Serial No.: 09/902,176

Filing Date: July 10, 2001

Confirmation No: 7507

Art Unit: 1634

Examiner: Sally A. Sakelaris

Title: DIAGNOSTIC USE OF POLYMORPHISMS IN THE GENE CODING FOR THE TNF
RECEPTOR II AND METHODS FOR DETECTING NON-RESPONDERS TO
ANTI-TNF THERAPY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to the provisions of 37 CFR §§ 1.56, 1.97 and 1.98, and MPEP 609, Applicant submits herewith copies of the documents listed on the attached Form SB/08B "Information Disclosure Statement by Applicant."

REMARKS

Consideration by the Examiner of each of the documents listed on Form SB/08B is respectfully requested. Applicant respectfully requests that a copy of SB/08B, as considered and initialed by the Examiner, be returned to the undersigned with the next Official Communication.


The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made. 37 CFR § 1.97(g). Furthermore, the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in this Statement is, or is considered to be, prior art, analogous art, or material to patentability of this application, but the information has been cited to make it clear beyond all doubt that Applicant's duty of disclosure has been complied with. 37 CFR § 1.97(h).

Applicant hereby submits that the claims of Applicant's above-referenced patent application are patentably distinguishable from these references.

It is believed that no fees are due; however, the Director is hereby authorized to charge any fees relating to this Information Disclosure Statement under 37 CFR § 1.17 to Deposit Account No 23-2426 of WINSTEAD SECHREST & MINICK P.C.


Respectfully submitted,

Date: Feb. 14, 2005


Melissa D. Schwaller
Registration No. 46,089

WINSTEAD SECHREST & MINICK P.C.
P.O. Box 50784
Dallas, Texas 75201
Telephone: 214.745.5633
Facsimile: 214.745.5390

ATTORNEYS FOR APPLICANT



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	09/902,176
	Filing Date	July 10, 2001
	First Named Inventor	Stefan Schreiber
	Art Unit	1634
	Examiner Name	Sally A. Sakelaris
	Attorney Docket Number	25481-P001US

Sheet	2	of	2
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ELLIOT, et al; Randomized double blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110, 1994.	
		FABRIS, et al.; Tumor Necrosis Factor-alpha Receptor II Polymorphism in Patients from Southern Europe with Mild-Moderate and Severe Rheumatoid Arthritis; http://www.jrheum.com/subscribers/02/09/1847.html ; December 14, 2004	
		OGILVIE, et al.; Treatment of psoriatic arthritis with antitumor necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate; British Journal of Dermatology 2001; 144: 587-589; UK	
		YEE, et al.; Treatment of Complicated Sarcoidosis with Infliximab Anti-tumor Necrosis Factor-Alpha Therapy; Annals of Internal Medicine; http://www.annals.org/cgi8/content/full/135/1/27 ; December 14, 2004	
		ARINGER, et al.; Safety and Efficacy of Tumor Necrosis Factor Alpha Blockade in Systemic Lupus Erythematosus; Arthritis & Rheumatism; American College of Rheumatology; Vol. 50, No. 10, October 2004; pp 3161-3169; US	
		RUTGEERTS, et al.; Treatment of active Crohn's diseases with oncept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study; Ailmentary Pharmacology & Therapeutics; Volume 17, Issue 2, Page 185, January 2003; http://www.blackwell-synergy.com/links/doi/10.1046/j.1365-2036.2003.01414.x/full/	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.